2022
FluoGuide has evaluated data from 8 patients in the exploratory phase IIa trial in patients with non-small cell lung cancer (NSCLC)...
20 October, 2022
FluoGuide has enrolled the first patient in the phase IIb trial in aggressive brain cancer
In the phase IIb trial, FG001 is being tested as a standalone treatment compared to Gliolan (5-ALA), which is the only approved product...
6 October, 2022
Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022
The excellent phase l/lla clinical data of FG001 in aggressive brain cancer will be presented by Principal Investigator and Chief Surgeon...
3 October, 2022
The excellent phase I/IIa clinical data of FG001 in aggressive brain cancer was presented at the World Molecular Imaging Congress
Andreas Kjaer, Professor and CSO at FluoGuide presented the excellent phase I/IIa clinical data of FG001 in aggressive brain cancer...
6 September, 2022
FluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer
Following the approval from the Danish Medicines Agency, FluoGuide is initiating the phase II trial in collaboration with Department...
31 August, 2022
FluoGuide appoints new CFO
Henrik Hang comes most recently from the role as CFO at Cyxone AB (publ). Henrik Hang has a degree in finance from University of Linné...
FluoGuide has now received approval from the Danish Ethical Committee and the trial can start in Denmark. FluoGuide announced in April...
In H1 2022, FluoGuide reached a major milestone in the clinical development showing that FG001 is very well tolerated and FG001 illuminates...
24 August, 2022
FluoGuide’s update on FG001’s clinical development
FluoGuide announced in April FG001’s highly promising results in aggressive brain cancer (high grade glioma) following its phase...